co-presented by
ASSOCIATE SPONSORS
co-presented by
ASSOCIATE SPONSORS
The trial will be conducted on 500 US patients, results of which are expected in FY17, says Venkat Jasti, Chairman and CEO of the company.
The clinical development program being executed through Suven, Inc., a Delaware Company in USA, wholly owned subsidiary of Suven Life Sciences.
Venkat Jasti, CEO of the company does not expect the second half of this fiscal year to be as robust as the first half. The first half saw additional revenue of Rs 100 crore on the back of the company supplying intermediates to innovators, which have finished phase three and are in the launch mode.
Venkat Jasti, CEO, Suven Life Sciences says that profit in the quarter jumped by 500 percent to Rs 7.7 crore due to the supply of a value-added compound, by the company‘s contract-research arm. Jasti told CNBC-TV18, in an interview after the announcement of results, that the company was preparing to fasttrack the development of SUVN-502.
Suven Life Science successfully completed Alzheimer drug, Suvn-502, phase I clinical trails and said it is filing for Investigational New Drug application with the US Food and Drug Administration.
